Levodopa neurotoxicity: Experimental studies versus clinical relevance

Neurology

Volumn 50, Issue 6 SUPPL.6, 1998, Pages

  Jenner, Peter G ^a   Brin, Mitchell F ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 8 HYDROXYGUANINE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; ANTIOXIDANT; BETA CARBOLINE DERIVATIVE; CATALASE; DEFEROXAMINE; DNA; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUTAMATE RECEPTOR ANTAGONIST; GLUTATHIONE; GLUTATHIONE PEROXIDASE; HYDROGEN PEROXIDE; HYDROXYL RADICAL; LEVODOPA; MELANIN; MONOAMINE OXIDASE INHIBITOR; N METHYL DEXTRO ASPARTIC ACID; OXIDOPAMINE; PYRUVIC ACID; QUINONE DERIVATIVE; REACTIVE OXYGEN METABOLITE; SEMIQUINONE; SUCCINIC ACID; SUPEROXIDE DISMUTASE; TETRAHYDROISOQUINOLINE DERIVATIVE;

APOPTOSIS; ARTICLE; AUTOOXIDATION; CLINICAL TRIAL; DOPAMINERGIC NERVE CELL; DYSKINESIA; HUMAN; LIPID PEROXIDATION; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL;

EID: 0031839755     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.50.6_suppl_6.s39     Document Type: Article

References (72)

1. Graham DG. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol 1978;14:633-643.
2. Cohen G. Oxygen radicals and Parkinson's disease. Upjohn Symposium/Oxygen Radicals, April 1987:130-135.
3. Spina MB, Cohen G. Exposure of striatal synaptosomes to L-DOPA increases levels of oxidized glutathione. J Pharmacol Exp Ther 1988;247:502-507.
4. Jenner P, Olanow CW. Oxidative stress and the pathogenesis of Parkinson's disease. Neurology 1996;47(suppl 3):S161-170.
5. Dexter DT, Carter CJ, Wells FR, et al. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease J Neurochem 1989;52:381-389.
6. Dexter DT, Holley AE, Flitter WD, et al. Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: an HPLC and ESR study. Mov Disord 1994;9:92-97.
7. Alam ZI, Daniel SE, Lees AJ, Marsden CD, Jenner P, Halliwell B. Oxidative damage in the parkinsonian brain: a selective increase in 8-hydroxyguanine in substantia nigra? J Neurochem 1997;69:1196-1203.
8. Alam ZI, Daniel SE, Lees AJ, Marsden CD, Jenner P, Halliwell B. A generalised increase in carbonyls in the brain in Parkinson's disease but not incidental Lewy body disease J Neurochem 1997;69:1326-1329.
9. Dexter DT, Sian S, Rose S, et al. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Ann Neurol 1994;35:38-44.
10. Schapira AHV, Mann VM, Cooper JM, et al. Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease. J Neurochem 1990;55:2142-2145.
11. Gu M, Gash MT, Cooper JM, et al. Mitochondrial respiratory chain function in multiple system atrophy. Mov Disord 1997; 12:418-422.
12. Fahn S. Levodopa-induced neurotoxicity: does it represent a problem for the treatment of Parkinson's disease? CNS Drugs 1997;8:376-393.
13. Spencer JPE, Jenner A, Butler J, et al. Evaluation of the pro-oxidant and antioxidant actions of L-DOPA and dopamine in vitro: implications for Parkinson's disease. Free Radic Res 1996;24:95-105.
14. Spencer JPE, Jenner A, Aruoma OI, et al. Intense oxidative DNA damage promoted by L-DOPA and its metabolites: implications for neurodegenerative disease. FEBS Lett 1994;353: 246-250.
15. Wick MM, Byers L, Frei E. L-DOPA: selective toxicity for melanoma cells in vitro. Science 1977;197:468-469.
16. Mena MA, Pardo B, Casarejos MJ, Fahn S, de Yébenes JG. Neurotoxicity of levodopa on catecholamine-rich neurons Mov Disord 1992;7:23-31.
17. Ziv I, Zilkha-Falb R, Offen D, Shirvan A, Barzilai A, Melamed E. Levodopa induces apoptosis in cultured neuronal cells: a possible accelerator of nigrostriatal degeneration in Parkinson's disease. Mov Disord 1997;12:17-23.
18. Walkinshaw G, Waters CM. Induction of apoptosis in catecholaminergic PC12 cells by L-DOPA: implications for the treatment of Parkinson's disease. J Clin Invest 1995;95:2458-2464.
19. Mena MA, Pardo B, Paino CL, de Yébenes JG. Levodopa toxicity in foetal rat midbrain neurones in culture: modulation by ascorbic acid. Neuroreport 1993;4:438-440.
20. Pardo B, Mena MA, Fahn S, de Yébenes JG. Ascorbic acid protects against levodopa-induced neurotoxicity on a catecholamine-rich human neuroblastoma cell line. Mov Disord 1993;8:278-284.
21. Offen D, Ziv I, Sternin H, Melamed E, Hochman A. Prevention of dopamine-induced cell death by thiol antioxidants: possible implications for treatment of Parkinson's disease. Exp Neurol 1996;141:32-39.
22. Mytilineou C, Han S-K, Cohen G. Toxic and protective effects of L-DOPA on mesencephalic cell cultures. J Neurochem 1993; 61:1470-1478.
23. Han S-K, Mytilineou C, Cohen G. L-DOPA up-regulates glutathione and protects mesencephalic cultures against oxidative stress. J Neurochem 1996;66:501-510.
24. Spencer JPE, Jenner P, Halliwell B. Superoxide-dependent depletion of reduced glutathione by L-DOPA and dopamine: relevance to Parkinson's disease. Neuroreport 1995;6:1480-1484.
25. Shen X-M, Dryhurst G. Further insights into the influence of L-cysteine on the oxidation chemistry of dopamine: reaction pathways of potential relevance to Parkinson's disease. Chem Res Toxicol 1996;9:751-763.
26. Masserana JM, Gong L, Kulaga H, Baker I, Wyatt RJ. Dopamine induces apoptotic cell death of a catecholaminergic cell line derived from the central nervous system. Mol Pharmacol 1996;50:1309-1315.
27. Hoyt KR, Reynolds IJ, Hastings TG. Mechanisms of dopamine-induced cell death in cultured rat forebrain neurons: interactions with and differences from glutamate-induced cell death. Exp Neurol 1997;143:269-281.
28. Ziv I, Melamed E, Nardi N, Offen D, Barzilai A. Dopamine induces apoptosis-like cell death in cultured sympathetic neurones: a possible novel pathogenic mechanism in Parkinson's disease. Neurosci Lett 1994;170:136-140.
29. Pardo B, Mena MA, Casarejos MJ, Paino CL, de Yébenes JG. Toxic effects of L-DOPA on mesencephalic cell cultures: protection with antioxidants. Brain Res 1995;682:133-143.
30. Basma AN, Morris EJ, Niclas WJ, Gella HM. L-DOPA cytotoxicity to PC12 cells in culture is via its auto-oxidation. J Neurochem 1995;64:825-832.
31. Tanaka M, Sotomatsu A, Kanai H, Hirai S. Dopa and dopamine cause cultured neuronal death in the presence of iron. J Neurol Sci 1991;101:198-203.
32. Tanaka M, Sotomatsu A, Kanai H, Hirai S. Combined histochemical and biochemical demonstration of nigral vulnerability to lipid peroxidation induced by DOPA and iron. Neurosci Lett 1992;140:42-46.
33. Olney JW, Zorumski CF, Stewart GR, Price MT, Wang G, Labruyere J. Excitotoxicity of L-DOPA and 6-OH-DOPA: implications for Parkinson's and Huntington's diseases. Exp Neurol 1990;108:269-272.
34. 2+-dependent and tetrodotoxin-sensitive release of endogenous glutamate from rat striatal slices. Brain Res 1993;617:167-170.
35. Cheng N, Maeda T, Kume T, et al. Differential neurotoxicity induced by L-DOPA and dopamine in cultured striatal neurones. Brain Res 1996;743:278-283.
36. Ziv I, Offen D, Barzilay A, Stein R, Melamed E. The protooncogene Bcl-2, a novel cellular protective mechanism against dopamine toxicity: possible implications for Parkinson's disease [abstract]. Neurology 1995;45(suppl 4):A279.
37. Pardo B, Mena MA, de Yébenes JG. L-DOPA inhibits complex IV of the electron transport chain in catecholamine-rich human neuroblastoma NB69 cells. J Neurochem 1995;64:576-582.
38. Ben-Shachar D, Zuk R, Glinka Y. Dopamine neurotoxicity: inhibition of mitochondrial respiration. J Neurochem 1995;64: 718-723.
39. Cohen G, Farooqui R, Kesler N. Parkinson's disease: a new link between monoamine oxidase and mitochondrial electron flow. Proc Natl Acad Sci USA 1997;94:4890-4894.
40. Cotzias GC, Miller ST, Tang LC, Papavasiliou PS. Levodopa, fertility and longevity. Science 1977;196:549-551.
41. Perry TL, Yong VW, Ito M, et al. Nigrostriatal dopamine neurons remain undamaged in rats given high doses of L-DOPA and carbidopa chronically. J Neurochem 1984;43: 990-993.
42. Hefti F Melamed E, Bhawan J, Wurtman RJ. Long-term administration of L-DOPA does not damage dopaminergic neurons in the mouse. Neurology 1981;31:1194-1195.
43. Melamed E, Rosenthal J. Can chronic levodopa therapy accelerate degeneration of dopaminergic neurons and progression of Parkinson's disease? In: Nagatsu T, Fisher A, Yoshida M, eds. Basic, clinical, and therapeutic aspects of Alzheimer's and Parkinson's diseases. New York: Plenum Press, 1990:253-256.
44. Perry TL, Yong VW, Ito M, et al. Nigrostriatal dopaminergic neurons remain undamaged in rats given high doses of L-DOPA and carbidopa chronically. J Neurochem 1984;43: 990-993.
45. Sahakian BJ, Carlson KR, DeGirolami U, Bhawan J. Functional and structural consequences of long-term dietary L-DOPA treatment in mice. Commun Psychopharmacol 1980; 4:169-176.
46. Papavasiliou PS, Miller ST, Thai LJ, et al. Age-related motor and catecholamine alterations in mice on levodopa-supplemented diet. Life Sci 1981;28:2945-2952.
47. Blunt SB, Jenner P, Marsden CD. Motor function, graft survival and gliosis in rats with 6-OHDA lesions and foetal ventral mesencephalic grafts chronically treated with L-DOPA and carbidopa. Exp Brain Res 1992;88:326-340.
48. Ogawa N, Asanuma M, Kondo Y, Kawada Y, Yamamoto M, Mori A. Differential effects of chronic L-DOPA treatment on lipid peroxidation in the mouse brain with or without pretreatment with 6-hydroxydopamine. Neurosci Lett 1994;171: 55-58.
49. Smith TS, Parker WD Jr, Bennett JP. L-dopa increases nigral production of hydroxyl radicals in vivo: potential levodopa toxicity? Neuroreport 1994;5:1009-1011.
50. +. J Neural Transm [Gen Sect] 1992;89:139-145.
51. Loeffler DA, DeMaggio AJ, Juneau PL, Havaich MK, LeWitt PA. Effects of enhanced striatal dopamine turnover in vivo on glutathione oxidation. Clin Neuropharmacol 1994;17:370-379.
52. Przeborski S, Jackson-Lewis V, Muthane U, et al. Chronic levodopa administration alters cerebral mitochondrial respiratory chain activity. Ann Neurol 1993;34:715-723.
53. Cooper JM, Daniel SE, Marsden CD, Schapira AHV. L-dihydroxyphenylalanine and complex I deficiency in Parkinson's disease brain. Mov Disord 1995;10:295-297.
54. Filloux F, Townsend JJ. Pre- and postsynaptic neurotoxic effects of dopamine demonstrated by intrastriatal injection. Exp Neurol 1993;119:79-88.
55. Blunt SB, Jenner P, Marsden CD. Suppressive effect of L-DOPA on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6-hydroxydopamine. Mov Disord 1993;8:129-133.
56. Naudin B, Bonnett JJ, Costentin J. Acute L-DOPA pretreatment potentiates 6-hydroxydopamine-induced toxic effects on nigrostriatal dopamine neurones in mice. Brain Res 1995;701: 151-157.
57. Melamed E, Rosenthal J, Reches A. Prenatal administration of levodopa is not toxic to fetal dopaminergic neurons in vivo [abstract]. Neurology 1992;42(suppl 3):378.
58. Collier KS, Collier TJ, Sladek CD, Sladek JR. Chronic levodopa impairs morphological development of grafted embryonic dopamine neurons. Exp Neurol 1990;110:201-208.
59. Blunt SB, Jenner P, Marsden CD. The effect of chronic L-DOPA treatment on the recovery of motor function in 6-hydroxydopamine-lesioned rats receiving ventral mesencephalic grafts. Neuroscience 1991;40:453-464.
60. 3H]mazindol autoradiography. Neuroscience 1991;43: 95-110.
61. Adams CE, Hoffman AF, Hudson JL, Hoffer BJ, Boyson SJ. Chronic treatment with levodopa and/or selegiline does not affect behavioral recovery induced by fetal ventral mesencephalic grafts in unilaterally 6-hydroxydopamine-lesioned rats. Exp Neurol 1994;130:261-268.
62. Quinn N, Parkes D, Janoto J, Marsden CD. Preservation of the substantia nigra and locus ceruleus in a patient receiving levodopa plus decarboxylase inhibitor over a four-year period. Mov Disord 1986;1:65-68.
63. Rajput AH, Fenton ME, Dhand A. Is levodopa toxic to nondegenerating substantia nigra cells? Clinical evidence [abstract]. Neurology 1996;46(suppl):A371.
64. Rajput AH, Fenton ME, Birdi S, Macaulay R. Is levodopa toxic to human substantia nigra? Mov Disord 1997;12:634-638.
65. Yahr MD, Wolf A, Antunes JL, Miyoshi K, Duffy P. Autopsy findings in parkinsonism following treatment with levodopa. Neurology 1970;6(suppl):55-56.
66. Maier Hoehn MM. Parkinsonism treated with levodopa: progression and mortality. J Neural Transm Suppl 1983;19:253-264.
67. Kordower JH, Freeman TB, Snow BJ, Olanow CW. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N Engl J Med 1995;332: 1118-1124.
68. Nagatsu T. Isoquinoline neurotoxins in the brain and Parkinson's disease. Neurosci Res 1997;29:99-111.
69. Niwa T, Takeda N, Yoshizumi H, et al. Presence of 2-methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline and 1,2-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, novel endogenous amines in parkinsonian and normal human beings. Biochem Biophys Res Commun 1991;177:603-609.
70. Walkinshaw G, Waters CM. Induction of apoptosis in catecholaminergic PC12 cells by L-DOPA: implications for the treatment of Parkinson's disease. J Clin Invest 1995;95:2458-2464.
71. 2 oxidation of dopamine. J Med Chem 1995;38:917-922.
72. Mena MA, Davila V, Sulzer D. Neurotrophic effects of L-DOPA in postnatal midbrain dopamine neuron/cortical astrocyte cocultures. J Neurochem 1997;69:1398-1408.